Photo by U.S. Army photo by Sgt. 1st Class Roddy Rieger via Creative Commons Attribution 2.0 Generic (Illustrative Purposes Only)
No sickler should have to suffer.
This is why we -- the Xickle team -- are dedicated not only to raising awareness about SCD, but also to developing products that can benefit sickle cell warriors of all ages. Most recently, we've begun our very own clinical trial in order to further our goal of receiving FDA-approval for Xickle RBC-Plus as a treatment for SCD. It may take up to seven years to receive such FDA approval. In the meantime, we are allowed to offer Xickle RBC-Plus as a supplement. We understand that people with SCD are bombarded with information about new drugs and supplements regularly, so to help you understand how Xickle RBC-Plus differs from other products you may have heard about, we'll be breaking things down in more detail below.
Basically, Xickle is an improved formulation of Nicosan (Nicosan/Niprisan was approved for the treatment of SCD in Nigeria) and is made up of the extracts from dried plants, one of them being sorghum bicolor leaves. It turns out, certain sorghum extracts have powerful anti-sickling activity.
During our research and development, we collected sorghum seeds from 19 countries, studied their germination, growth, and ability to respond to being mixed with different compounds thought to help encourage the anti-sickling property. Those seeds were then planted, harvested monthly, and analyzed. This research resulted in increased potency of the product, as well as advanced methods of standardizing the way the product is made. These strides will allow us to efficiently mass produce Xickle. This research is a big step forward in helping us reach our FDA-approval goals.
Read this and this, too, for even more information on our research and tell us your thoughts in the comments below!
